Биология ва тиббиёт муаммолари 2026, №2 (168)

Subject of the article

PHARMACOLOGICAL TREATMENT OF MULTIPLE SCLEROSIS USING DISEASE-MODIFYING THERAPIES (239-242)

Authors

Ochilova Dilafruz Furkatovna, Mizamov Furkat Ochilovich

Institution

1 - Tashkent State Medical University, Republic of Uzbekistan, Tashkent; 2 - Samarkand State Medical University, Republic of Uzbekistan, Samarkand

Abstract

This article is devoted to the study of the therapy of multiple sclerosis. Multiple sclerosis is a chronic disease, and it is not possible to cure it forever due to the absence of the only correct therapeutic method. Immunomodulatory therapy can be used to treat recurrent forms of MS. There is no consensus on the choice of immunomodulatory therapy that changes the course of the disease. Most experts recommend instructing the patient and making deci-sions together, including when immunomodulatory therapy is offered to patients with clinically isolated syndrome and who have more than one pathological change.

Key words

multiple sclerosis, drug, immunomodulatory therapy, patient.

Literature

1. Burton JM, O'Connor PW, Hohol M, Beyene J: Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. Cochrane Database Syst Rev 12:CD006921, 2012. 2. Filippi M, Rocca MA, Ciccarelli O, et al: MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol 15(3):292–303, 2016. 3. Freedman MS, Devonshire V, Duquette P, et al: Treatment optimization in multiple sclerosis: Cana-dian MS working group recommendations. Can J Neurol Sci 47(4):437–455, 2020. 4. Granqvist M, Boremalm M, Poorghobad A, et al: Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurol 75(3):320–327, 2018. 5. Hauser SL, Bar-Or A, Comi G, et al: Ocrelizumab versus interferon beta-1a in relapsing multiple scle-rosis. N Engl J Med 376(3):221–234, 2017. 6. Le Page E, Veillard D, Laplaud DA, et al: Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple scle-rosis (COPOUSEP): A randomised, controlled, dou-ble-blind, non-inferiority trial. Lancet 386(9997):974–981, 2015. doi: 10.1016/S0140-6736(15)61137-0 7. Li H, Hu F, Zhang Y, Li K: Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing–remitting multiple sclerosis: A systematic review and network meta-analysis. J Neurol 267(12):3489–3498, 2020. 8. Multiple Sclerosis Society of Canada: Vitamin D and Multiple Sclerosis Recommendations. Accessed 3/9/21 9. Rae-Grant A, Day GS, Marrie RA, et al: Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclero-sis: Report of the Guideline Development, Dissemi-nation, and Implementation Subcommittee of the American Academy of Neurology. Neurology 90(17):777–788, 2018.